Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
ATOSRecognized for Visionary Leadership and Advancing Innovative Therapies in Oncology and Healthcare Technology SEATTLE, Jan. 21, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies...
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
ATOSDesignation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation SEATTLE, Jan. 16, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage...
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
ATOSSEATTLE, Jan. 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") issued a "Study May Proceed" letter for...
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
ATOSRecognized for Advancing (Z)-Endoxifen, a Precision-Engineered Endocrine Therapy with Potential Across Multiple Breast Cancer and Rare Disease Settings SEATTLE, Dec. 17, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage...
Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference
ATOSDr. Steven Quay, Chairman and Chief Executive Officer to participate in Fireside Chat with Emily Bodnar, HCW Biotech Research Analyst SEATTLE, Aug. 28, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company...
Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer
ATOSMonotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025 Topline results anticipated in 2026 Positions Atossa for transition into registrational Phase 3 development SEATTLE, Aug. 20, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the...
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.5
ATOSThis Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
ATOSCraig-Hallum Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $4
ATOSAtossa Therapeutics Reports Full Results From Phase 2 EOP Sub‑Study Within I‑SPY 2 Trial Evaluating Low‑Dose Oral (Z)‑Endoxifen As Neoadjuvant Treatment In 20 Women With Stage II/III ER+, HER2‑Negative Breast Cancer
ATOSAtossa Therapeutics Q1 EPS $(0.05) Beats $(0.06) Estimate
ATOSAtossa Therapeutics Awarded U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations For Its (Z)-Endoxifen Portfolio
ATOSAtossa Therapeutics Outlines Framework For Pioneering Phase 3 Clinical Study Titled SMART 2.0 At AACR 2025
ATOSAtossa Therapeutics: USPTO Grants New Patent Directed To Enteric Oral Formulations Comprising (Z)-endoxifen As Well As Methods Of Treating Subjects With Oral Formulations
ATOSAscendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.25
ATOSAtossa Therapeutics Files Petition For Post Grant Review Against Company; Intas Pharmaceuticals Files Petition For Inter Partes Review Against Company; To Contest PGR and LPR Petitions
ATOSHC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $7 Price Target
ATOSAtossa Therapeutics FY 2024 GAAP EPS $(0.20) Beats $(0.22) Estimate, Cash $71.1M
ATOSHC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $7 Price Target
ATOSAtossa Therapeutics Announces Shift Towards Metastatic Breast Cancer Indication For (Z)-Endoxifen, Aiming For Efficient Regulatory Pathway; Plans FDA Collaboration For Additional Indications
ATOSAtossa Therapeutics To Present Five Abstracts For Data Regarding (Z)-Endoxifen At 2024 San Antonio Breast Cancer Symposium
ATOSHC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target
ATOSAtossa Therapeutics Reports Phase 2 Data for Breast Cancer Prevention
ATOSHC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target
ATOSAtossa Therapeutics Releases Preliminary Analysis From Phase 2 Trial Of (Z)-endoxifen As Part Of I-SPY 2 Endocrine Optimization Pilot Will Be Subject Of Poster Presentation At Inaugural RISE UP Breast Cancer Conference
ATOS